GlassScriptPhysician profile
Edward K Scanlon
NPI 1699777128
$2,445.18
in general payments reported to CMS, 2019-2025
19 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $563 · 2020: $271 · 2021: $12.47 · 2022: $802 · 2023: $663 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $798.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $798.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $577.03 | 2020-2023 | Fasenra, Tagrisso, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $322.31 | 2019-2023 | Ofev |
| Mallinckrodt Hospital Products INC. | $276.35 | 2022-2023 | Acthar |
| Intuitive Surgical, INC. | $250.16 | 2022-2025 | |
| Glaxosmithkline, LLC. | $179.85 | 2019-2023 | Trelegy Ellipta, Nucala, Arexvy |
| Grifols USA, LLC | $132.04 | 2019-2020 | |
| Inspire Medical Systems, INC. | $120.00 | 2022 | |
| Insmed, INC. | $111.48 | 2019 | |
| Jazz Pharmaceuticals INC. | $88.90 | 2019 | |
| Genzyme Corporation | $83.44 | 2022-2023 | |
| Pulmonx Corporation | $65.82 | 2023 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Sunovion Pharmaceuticals INC. | $57.66 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $49.25 | 2019 | |
| Abbvie INC. | $33.17 | 2023 | Teflaro |
| Kaleo, INC. | $32.31 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $20.73 | 2019 | |
| Medtronic Vascular, INC. | $16.45 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.39 | 2022 | |
| Fisher & Paykel Healthcare INC | $12.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Scanlon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.